https://doi.org/10.17116/profmed201619115-23. EDN: VSEPLP.

2. Evstifeeva S.E., Metelskaya V.A., Drapkina O.M., Boytsov S.A. Lipoprotein(a) in an adult sample from the Russian population: Distribution and association with atherosclerotic cardiovascular diseases. Arch Med Sci. 2021; 19(4): 995–1002.

https://doi.org/10.5114/aoms/131089. PMID: 37560742. PMCID: PMC10408034.

3. Castelli W.P. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol. 1992; 70(19): 3H–9H.

https://doi.org/10.1016/0002-9149(92)91083-G. PMID: 1466315.

4. Hegele R.A., Ginsberg H.N., Chapman M.J. et al. The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management. Lancet Diabetes Endocrinology. 2014; 2(8): 655–66.

https://doi.org/10.1016/S2213-8587(13)70191-8. PMID: 24731657. PMCID: PMC4201123.

5. Yuan G., Al-Shali K.Z., Hegele R.A. Hypertriglyceridemia: Its etiology, effects and treatment. Can Med Assoc J. 2007; 176(8): 1113–20.

https://doi.org/10.1503/cmaj.060963. PMID: 17420495. PMCID: PMC1839776.

6. Boren J., Williams K.J. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: A triumph of simplicity. Curr Opin Lipidol. 2016; 27(5): 473–83.

https://doi.org/10.1097/MOL.0000000000000330. PMID: 27472409.

7. Heo J.H., Jo S.H. Triglyceride-rich lipoproteins and remnant cholesterol in cardiovascular disease. J Korean Med Sci. 2023; 38(38): e295.

https://doi.org/10.3346/jkms.2023.38.e295. PMID: 37750369.

8. Zou Y.W., Wu T., Li Q.H. et al. L. Association of serum concentrations of remnant cholesterol with incident cardiovascular disease in patients with rheumatoid arthritis: A real-world data from 2001 to 2022. Int J Cardiol. 2024; 405: 131947.

https://doi.org/10.1016/j.ijcard.2024.131947. PMID: 38458390.

9. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration; Sarwar N., Sandhu M.S., Ricketts S.L. et al. Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies. Lancet. 2010; 375(9726): 1634–39. https://doi.org/10.1016/S0140-6736(10)60545-4. Erratum in: Lancet. 2010; 376(9735): 90. Kastelein, J.J. (added). PMID: 20452521. PMCID: PMC2867029.

10. Varbo A., Nordestgaard B.G. Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction. Eur Heart J. 2021; 42(47): 4833–43.

https://doi.org/10.1093/eurheartj/ehab293. PMID: 34023898.

11. Lawler P.R., Kotrri G., Koh M. et al. Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Eur Heart J. 2020; 41(1): 86–94.

https://doi.org/10.1093/eurheartj/ehz767. PMID: 31733058.

12. Lewis G.F., Xiao C., Hegele R.A. Hypertriglyceridemia in the genomic era: A new paradigm. Endocr Rev. 2015; 36(1): 131–47.

https://doi.org/10.1210/er.2014-1062. PMID: 25554923.

13. Zhao M., Xiao M., Tan Q., Ji J., Lu F. Cumulative residual cholesterol predicts the risk of cardiovascular disease in the general population aged 45 years and older. Lipids Health Dis. 2024; 23(1): 19.

https://doi.org/10.1186/s12944-023-02000-0. PMID: 38243226.

14. Wu W., Chen G., Wu K. et al. Cumulative exposure to high remnant-cholesterol concentrations increases the risk of cardiovascular disease in patients with hypertension: A prospective cohort study. Cardiovasc Diabetol. 2023; 22(1): 258.

https://doi.org/10.1186/s12933-023-01984-4. PMID: 37735420. PMCID: PMC10515262.

15. Wadstrom B.N., Pedersen K.M., Wulff A.B., Nordestgaard B.G. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur Heart J. 2023; 44(16): 1432–45.

https://doi.org/10.1093/eurheartj/ehac822. PMID: 36631967.

16. Sturzebecher P.E., Katzmann J.L., Laufs U. What is ‘remnant cholesterol’? Eur Heart J. 2023; 44(16): 1446–48.

https://doi.org/10.1093/eurheartj/ehac783. PMID: 36650915.

17. Wadstrom B.N., Wulff A.B., Pedersen K.M. et al. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: A cohort-based study. Eur Heart J. 2022; 43(34): 3258–69.

https://doi.org/10.1093/eurheartj/ehab705. PMID: 34661640.

18. Doi T., Nordestgaard B.G., Langsted A. Can remnant cholesterol (triglyceride-rich lipoproteins) reclassify estimated risk of atherosclerotic cardiovascular disease? Curr Opin Endocrinol Diabetes Obes. 2023; 30(2): 128–35.

https://doi.org/10.1097/MED.0000000000000799. PMID: 36722437.

19. Larsen B.S., Olsen F.J., Andersen D.M. et al. Left Atrial volumes and function, and long-term incidence of ischemic stroke in the general population. J Am Heart Assoc. 2022; 11(18): e027031.

https://doi.org/10.1161/JAHA.122.027031. PMID: 36073645

20. Dinu M, Pagliai G, Casini A, Sofi F. Mediterranean diet and multiple health outcomes: An umbrella review of meta-analyses of observational studies and randomised trials. Eur J Clin Nutr. 2018; 72(1): 30–43.

https://doi.org/10.1038/ejcn.2017.58. PMID: 28488692.

21. Georgoulis M., Chrysohoou C., Georgousopoulou E. et al. Long-term prognostic value of LDL-C, HDL-C, lp(a) and TG levels on cardiovascular disease incidence, by body weight status, dietary habits and lipid-lowering treatment: The ATTICA epidemiological cohort study (2002–2012). Lipids Health Dis. 2022; 21(1): 141.

https://doi.org/10.1186/s12944-022-01747-2. PMID: 36529737.

22. Barter P., Gotto A.M., LaRosa J.C. et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007; 357(13): 1301–10. https://doi.org/10.1056/NEJMoa064278. PMID: 17898099.

23. Carey V.J., Bishop L., Laranjo N. et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010; 106(6): 757–63.

https://doi.org/10.1016/j.amjcard.2010.05.002. PMID: 20816113. PMCID: PMC4102341.

24. Боева О.И., Кокорин В.А., Хрипунова А.А. Возможности комбинированной гиполипидемической терапии смешанной атерогенной дислипидемии. Терапия. 2022; 8(1): 162–173. (Boeva O.I., Kokorin V.A., Khripunova A.A. Combined hypolipidemic therapy for mixed atherogenic dyslipidemia: A review. Terapiya = Therapy. 2022; 8(1): 162–173 (In Russ.)).

https://doi.org/10.18565/therapy.2022.1.162-173. EDN: DNIHDJ.

25. Sathiyakumar V., Park J., Golozar A. et al. Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy. Circulation. 2018; 137(1): 10–19.

https://doi.org/10.1161/circulationaha.117.030677. PMID: 29038168.

26. Sniderman A.D., Islam S., Yusuf S., McQueen M.J. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis. 2012; 225(2): 444–49.

https://doi.org/10.1016/j.atherosclerosis.2012.08.039. PMID: 23068583.

27. Шальнова С.А., Метельская В.А., Куценко В.А. с соавт. Холестерин, не входящий в состав липопротеинов высокой плотности: современный ориентир оценки нарушений липидного обмена. Рациональная фармакотерапия в кардио­логии. 2022; 18(4): 366–375 (Shalnova S.A., Metelskaya V.A., Kutsenko V.A. et al. Cholesterol that is not part of high-density lipoprotein: A modern benchmark for assessing lipid metabolism disorders. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2022; 18(4): 366–375 (In Russ.)).

https://doi.org/10.20996/1819-6446-2022-07-01. EDN: PSCNVF.

28. Mach F., Baigent C., Catapano A.L. et al. 2019 Рекомендации ESC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска. Российский кардиологический журнал. 2020; 25(5): 121–193. (Mach F., Baigent C., Catapano A.L. et al. 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 25(5): 121–193 (In Russ.)).

https://doi.org/10.15829/1560-4071-2020-3826. EDN: FDLIIW.

29. Ежов М.В., Кухарчук В.В., Сергиенко И.В. с соавт. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023; 28(5): 250–297. (Ezhov M.V., Kukharchuk V.V., Sergienko I.V. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2023; 28(5): 250–297 (In Russ.)).

https://doi.org/10.15829/1560-4071-2023-5471. EDN: YVZOWJ.

30. Marston N.A., Giugliano R.P., Im K. et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: A systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019; 140(16): 1308–17.

https://doi.org/10.1161/circulationaha.119.041998. PMID: 31530008. PMCID: PMC6791781.

31. Brien S.E., Ronksley P.E., Turner B.J. et al. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: Systematic review and meta-analysis of interventional studies. BMJ. 2011; 342: d636.

https://doi.org/10.1136/bmj.d636. PMID: 21343206. PMCID: PMC3043110.

32. Huffman K.M., Hawk V.H., Henes S.T. et al. Exercise effects on lipids in persons with varying dietary patterns – does diet matter if they exercise? Responses in studies of a targeted risk reduction intervention through defined exercise I. Am Heart J. 2012; 164(1): 117–24.

https://doi.org/10.1016/j.ahj.2012.04.014. PMID: 22795291. PMCID: PMC3399760.

33. Taskinen M.R., Soderlund S., Bogl L.H. et al. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity. J Intern Med. 2017; 282(2): 187–201.

https://doi.org/10.1111/joim.12632. PMID: 28548281.

34. Rivellese A.A., Maffettone A., Vessby B. et al. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects. Atherosclerosis. 2003; 167(1): 149–58.

https://doi.org/10.1016/s0021-9150(02)00424-0. PMID: 12618280.

35. Preiss D., Tikkanen M.J., Welsh P. et al. Lipidmodifying therapies and risk of pancreatitis: A meta-analysis. JAMA. 2012; 308(8): 804–11.

https://doi.org/10.1001/jama.2012.8439. PMID: 22910758.

36. Cholesterol Treatment Trialists Collaboration, Baigent C., Blackwell L., Emberson J. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670–81.

https://doi.org/10.1016/S0140-6736(10)61350-5. PMID: 21067804. PMCID: PMC2988224.

37. American Diabetes Association. 9. Cardiovascular disease and risk management: Standards of medical care in diabetes – 2018. Diabetes Care. 2018; 41(Suppl 1): S86–S104.

https://doi.org/10.2337/dc18-S009. PMID: 29222380.

38. Averna M., Banach M., Bruckert E. et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021; 325: 99–109.

https://doi.org/10.1016/j.atherosclerosis.2021.03.039. PMID: 33892925.

39. Li Y.H., Ueng K.C., Jeng J.S. et al. 2017 Taiwan lipid guidelines for high risk patients. J Formos Med Assoc. 2017; 116(4): 217–48.

https://doi.org/10.1016/j.jfma.2016.11.013. PMID: 28242176.

40. Keating G.M., Croom K.F. Fenofibrate: A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007; 67(1): 121–53.

https://doi.org/10.2165/00003495-200767010-00013. PMID: 17209672.

41. ACCORD Study Group, Ginsberg H.N., Elam M.B., Lovato L.C. et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1563–74.

https://doi.org/10.1056/nejmoa1001282. PMID: 20228404. PMCID: PMC2879499.

42. Keech A., Simes R.J., Barter P. et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005; 366(9500): 1849–61.

https://doi.org/10.1016/S0140-6736(05)67667-2. PMID: 16310551.

43. Kandoussi A., Martin F., Hazzan M. et al. HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. Clin Sci (Lond). 2002; 103 Suppl 48: 81S–83S.

https://doi.org/10.1042/CS103S081S. PMID: 12193060.

44. Rudkowska I., Verreault M., Barbier O., Vohl M.C. Differences in transcriptional activation by the two allelic (L162V Polymorphic) variants of PPARα after Omega-3 fatty acids treatment. PPAR Res. 2009; 2009: 369602.

https://doi.org/10.1155/2009/369602. PMID: 19266045. PMCID: PMC2649533.

45. Xu X., Guo H., Jing Z. et al. N-oleoylethanolamine reduces inflammatory cytokines and adhesion molecules in TNF-α-induced human umbilical vein endothelial cells by activating CB2 and PPAR-α. J Cardiovasc Pharmacol. 2016; 68(4): 280–91.

https://doi.org/10.1097/FJC.0000000000000413. PMID: 27281236.

46. Frick M.H., Elo O., Haapa K. et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317(20): 1237–45.

https://doi.org/10.1056/NEJM198711123172001. PMID: 3313041.

47. Rubins H.B., Robins S.J., Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341(6): 410–18.

https://doi.org/10.1056/NEJM199908053410604. PMID: 10438259.

48. Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Circulation. 1992; 86(3): 839–48.

https://doi.org/10.1161/01.cir.86.3.839. PMID: 1516196.

49. Elam M.B., Ginsberg H.N., Lovato L.C. et al; ACCORDION Study Investigators. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017; 2(4): 370–80.

https://doi.org/10.1001/jamacardio.2016.4828. PMID: 28030716. PMCID: PMC5470410.

50. Das Pradhan A., Glynn R.J., Fruchart J.C. et al. PROMINENT Investigators. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022; 387(21): 1923–34.

https://doi.org/10.1056/NEJMoa2210645. PMID: 36342113.

51. Kim N.H., Kim S.G. Fibrates revisited: Potential role in cardiovascular risk reduction. Diabetes Metab J. 2020; 44(2): 213–21.

https://doi.org/10.4093/dmj.2020.0001. PMID: 32347023.

52. Berberich A.J., Hegele R.A. A Modern approach to dyslipidemia. Endocr. Rev. 2022; 43(4): 611–53.

https://doi.org/10.1210/endrev/bnab037. PMID: 34676866. PMCID: PMC9277652.

53. Bhatt D.L., Steg P.G., Miller M. et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019; 380(1): 11–22.

https://doi.org/10.1056/NEJMoa1812792. PMID: 30415628.

54. Rohit D., Shankar J. Comparative study of atorvastatin and rosuvastatin in combination with fenofibrate in mixed hyperlipidemia. Int J Pharmacol Clin Sci. 2016; 5(1): 25–31.

https://doi.org/10.5530/ijpcs.5.1.5.

55. Gaita L., Timar B., Timar R. et al. Lipid disorders management strategies (2024) in prediabetic and diabetic patients. Pharmaceuticals (Basel). 2024; 17(2): 219.

https://doi.org/10.3390/ph17020219. PMID: 38399434. PMCID: PMC10892910.

56. Aygun S, Tokgozoglu L. Comparison of current international guidelines for the management of dyslipidemia. J Clin Med. 2022; 11(23): 7249.

https://doi.org/10.3390/jcm11237249. PMID: 36498823.

57. Davidson M.H., Armani A., McKenney J.M., Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol. 2007; 99(6A): 3C–18C.

https://doi.org/10.1016/j.amjcard.2006.11.016. PMID: 17368275.

58. Jun M., Bin Zhu B., Tonelli M. et al. Effects of fibrates in kidney disease. A systematic review and meta-analysis. J Am Coll Cardiol. 2012; 60(20): 2061–71.

https://doi.org/10.1016/j.jacc.2012.07.049. PMID: 23083786.

59. Grundy S.M., Vega G.L., Yuan Z. et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005; 95(4): 462–68.

https://doi.org/10.1016/j.amjcard.2004.10.012. PMID: 15695129.

60. Ferdinand K.C., Davidson M.H., Kelly M.T., Setze C.M. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: Evaluation of dose-response. Am J Cardiovasc Drugs. 2012; 12(2): 117–25.

https://doi.org/10.2165/11597940-000000000-00000. PMID: 22263674.

61. Ray K.K., Reeskamp L.F., Laufs U. et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022; 43(8): 830–33.

https://doi.org/10.1093/eurheartj/ehab718. PMID: 34636884.

62. Государственный реестр лекарственных средств Минздрава России. Инструкции по медицинскому применению лекарственных препаратов с МНН фенофибрат. Доступ: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=Фенофибрат&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&regtype=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1 (дата обращения – 11.10.2024). (State register of medicines of the Ministry of Healthcare of Russia. Instructions for medical use of medicinal products with the INN fenofibrate. URL: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=Фенофибрат&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&regtype=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1 (date of access – 11.10.2024) (In Russ.)).

63. Baumgartner A., Drame K., Geutjens S., Airaksinen M. Does the polypill improve patient adherence compared to its individual formulations? A Systematic Review. Pharmaceutics. 2020; 12(2): 190.

https://doi.org/10.3390/pharmaceutics12020190. PMID: 32098393. PMCID: PMC7076630.

64. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Супрозафен. РУ: ЛП-№(000796)-(РГ-RU) от 20.11.2023. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5384ed94-b39a-4c45-85d1-c0b419cc6849 (дата обращения – 11.10.2024). (State register of medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the drug Suprozafen. Registration certificate: ЛП-№(000796)-(РГ-RU) from 11/20/2023. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5384ed94-b39a-4c45-85d1-c0b419cc6849 (date of access – 11.10.2024) (In Russ.)).

https://doi.org/10.2165/11319800-000000000-00000. PMID: 19995098.

65. Dixit R., Jagan S. Comparative study of atorvastatin and rosuvastatin in combination with fenofibrate in mixed hyperlipidemia. Int J Pharmacol Clin Sci. 2016; 5(1): 25–31.

https://doi.org/10.5530/ijpcs.5.1.5.

66. Tenenbaum A., Medvedofsky D., Fisman E.Z. et al. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. PLoS One. 2012; 7(4): e35298.

https://doi.org/10.1371/journal.pone.0035298. PMID: 22523582. PMCID: PMC3327654.

67. Pappa E., Rizos C.V., Filippatos T.D., Elisaf M.S. Emerging fixed-dose combination treatments for hyperlipidemia. J Cardiovasc Pharmacol Ther. 2019; 24(4): 315–22.

https://doi.org/10.1177/1074248419838506. PMID: 30909733.

68. Jones P.H., Davidson M.H., Stein E.A. et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial). Am J Cardiol. 2003; 92(2): 152–60.

https://doi.org/10.1016/s0002-9149(03)00530-7. PMID: 12860216.

69. Pepine C.J., Jacobson T.A., Carlson D.M. et al. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: Subanalysis of two randomized, controlled studies. Clin Cardiol. 2010; 33(10): 609–19.

https://doi.org/10.1002/clc.20830. PMID: 20960535. PMCID: PMC6653092.

70. Zhu T., Awni W.M., Hosmane B. et al. ABT-335, the Choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol. 2009; 49(1): 63–71.

https://doi.org/10.1177/0091270008325671. PMID: 18952910.